PHARMO’s annual scientific report discusses the current expertise and research of the PHARMO Institute, publications,

Hospitalisation rates for predefined safety outcomes (gastroenteritis, convulsion/seizure, pneumonia, thrombocytopenia, acute interstitial nephritis, angioneurotic oedema

Ron Herings van PHARMO over big data

Renal function, estimated by different measures of eGFR, is not associated with serious bleeding events

Longer exposure to HbA1c levels above target (i.e. HbA1c ≥64 mmol/mol (8%)) is associated with

A strong decrease in the use of cyproterone acetate (CPA) 2 mg, in combination with

PHARMO’s annual scientific report discusses the current expertise and research of the PHARMO Institute, publications,

Metformin is the most common initial type 2 diabetes (T2DM) treatment in the Netherlands, Italy,

Research confirms: concerns were justified Today the results of the study into the consequences of

In the current issue: A validated algorithm for asthma and COPD, ISO certificates for PHARMO and